Abstract
Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F substitution was higher among non-responder, compared to responder patients (33.7% vs. 17%, P = 0.0005), whereas the prevalence of the 184V and of the 70R mutations was comparable between these two groups. The 74V substitution was never observed and the 75T mutation was detected in only two subjects non-responder to a stavudine including regimen. Reduced susceptibility to didanosine or stavudine was infrequent. Reduced susceptibility to zidovudine was observed in 25% of individuals failing a zidovudine including regimen, whereas reduced susceptibility to lamivudine was detected in all subjects failing a lamivudine including regimen. In the prospective analysis, patients with undetectable viral load at enrollment had a lower incidence of failure rate over one year compared to those with detectable HIV-RNA at entry (P <0.0001). A detectable viral load at enrollment was the only independent variable that predicted clinical failure over one year (P <0.0001).
| Original language | English |
|---|---|
| Pages (from-to) | 129-139 |
| Number of pages | 11 |
| Journal | International Journal of Immunopathology and Pharmacology |
| Volume | 15 |
| Issue number | 2 |
| Publication status | Published - 2002 |
Fingerprint
Keywords
- Drug resistance
- HIV
- Nucleoside reverse transcriptase inhibitor (NRTI)
- Prospective study
ASJC Scopus subject areas
- Pharmacology
Cite this
Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues : The SMART study. / Gianotti, Nicola; Setti, M.; Manconi, P. E.; Leoncini, F.; Chiodo, F.; Minoli, L.; Moroni, M.; Angarano, G.; Mazzotta, F.; Carosi, G.; Antonelli, G.; Lazzarin, A.
In: International Journal of Immunopathology and Pharmacology, Vol. 15, No. 2, 2002, p. 129-139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues
T2 - The SMART study
AU - Gianotti, Nicola
AU - Setti, M.
AU - Manconi, P. E.
AU - Leoncini, F.
AU - Chiodo, F.
AU - Minoli, L.
AU - Moroni, M.
AU - Angarano, G.
AU - Mazzotta, F.
AU - Carosi, G.
AU - Antonelli, G.
AU - Lazzarin, A.
PY - 2002
Y1 - 2002
N2 - Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F substitution was higher among non-responder, compared to responder patients (33.7% vs. 17%, P = 0.0005), whereas the prevalence of the 184V and of the 70R mutations was comparable between these two groups. The 74V substitution was never observed and the 75T mutation was detected in only two subjects non-responder to a stavudine including regimen. Reduced susceptibility to didanosine or stavudine was infrequent. Reduced susceptibility to zidovudine was observed in 25% of individuals failing a zidovudine including regimen, whereas reduced susceptibility to lamivudine was detected in all subjects failing a lamivudine including regimen. In the prospective analysis, patients with undetectable viral load at enrollment had a lower incidence of failure rate over one year compared to those with detectable HIV-RNA at entry (P <0.0001). A detectable viral load at enrollment was the only independent variable that predicted clinical failure over one year (P <0.0001).
AB - Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F substitution was higher among non-responder, compared to responder patients (33.7% vs. 17%, P = 0.0005), whereas the prevalence of the 184V and of the 70R mutations was comparable between these two groups. The 74V substitution was never observed and the 75T mutation was detected in only two subjects non-responder to a stavudine including regimen. Reduced susceptibility to didanosine or stavudine was infrequent. Reduced susceptibility to zidovudine was observed in 25% of individuals failing a zidovudine including regimen, whereas reduced susceptibility to lamivudine was detected in all subjects failing a lamivudine including regimen. In the prospective analysis, patients with undetectable viral load at enrollment had a lower incidence of failure rate over one year compared to those with detectable HIV-RNA at entry (P <0.0001). A detectable viral load at enrollment was the only independent variable that predicted clinical failure over one year (P <0.0001).
KW - Drug resistance
KW - HIV
KW - Nucleoside reverse transcriptase inhibitor (NRTI)
KW - Prospective study
UR - http://www.scopus.com/inward/record.url?scp=0036295817&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036295817&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0036295817
VL - 15
SP - 129
EP - 139
JO - International Journal of Immunopathology and Pharmacology
JF - International Journal of Immunopathology and Pharmacology
SN - 0394-6320
IS - 2
ER -